Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPSMarket Beat·Aug 8 at 12:56 PMLYEL+1.17%BCS+1.28%
Lyell net loss widens to $44.76 million in Q2 FY26; revenue drops to $4,000PUBT·Aug 6 at 03:47 PMLYEL+1.17%
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursdaybenzinga_article·Aug 6 at 09:12 AMRNA-2.08%LYEL+1.17%
Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma share sale worth $137PUBT·Jul 20 at 01:56 PMLYEL+1.17%
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of "Moderate Buy" by BrokeragesMarket Beat·Jul 19 at 03:14 AMLYEL+1.17%
Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma common share disposal worth $137.3PUBT·Jul 17 at 08:45 PMLYEL+1.17%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jul 6 at 07:05 AMUPC-0.56%LUCY-0.09%
Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% ownerPUBT·Jun 18 at 03:07 PMLYEL+1.17%
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress | LYEL Stock NewsStockTitan·Jun 12 at 03:45 AMLYEL+1.17%
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion | LYEL Stock NewsStockTitan·Jun 7 at 09:00 PMLYEL+1.17%
